Immunogen Stock Earnings Per Share
| IMGNDelisted Stock | USD 18.20 0.81 4.26% |
ImmunoGen fundamentals help investors to digest information that contributes to ImmunoGen's financial success or failures. It also enables traders to predict the movement of ImmunoGen Stock. The fundamental analysis module provides a way to measure ImmunoGen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmunoGen stock.
ImmunoGen |
ImmunoGen Company Earnings Per Share Analysis
ImmunoGen's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current ImmunoGen Earnings Per Share | (0.28) X |
Most of ImmunoGen's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmunoGen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, ImmunoGen has an Earnings Per Share of -0.28 times. This is 103.35% lower than that of the Biotechnology sector and 94.15% lower than that of the Health Care industry. The earnings per share for all United States stocks is 108.97% higher than that of the company.
ImmunoGen Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmunoGen's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ImmunoGen could also be used in its relative valuation, which is a method of valuing ImmunoGen by comparing valuation metrics of similar companies.ImmunoGen is currently under evaluation in earnings per share category among its peers.
ImmunoGen Fundamentals
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0849 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 8.2 B | |||
| Shares Outstanding | 279.35 M | |||
| Shares Owned By Insiders | 0.32 % | |||
| Shares Owned By Institutions | 91.29 % | |||
| Number Of Shares Shorted | 20.61 M | |||
| Price To Earning | (4.49) X | |||
| Price To Book | 15.53 X | |||
| Price To Sales | 30.33 X | |||
| Revenue | 287.61 M | |||
| Gross Profit | (104.76 M) | |||
| EBITDA | (78.46 M) | |||
| Net Income | (73.52 M) | |||
| Cash And Equivalents | 373.87 M | |||
| Cash Per Share | 1.69 X | |||
| Total Debt | 15.24 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 4.52 X | |||
| Book Value Per Share | 2.06 X | |||
| Cash Flow From Operations | (197.89 M) | |||
| Short Ratio | 3.78 X | |||
| Earnings Per Share | (0.28) X | |||
| Target Price | 31.06 | |||
| Number Of Employees | 277 | |||
| Beta | 1.17 | |||
| Market Capitalization | 8.72 B | |||
| Total Asset | 348.94 M | |||
| Retained Earnings | (1.69 B) | |||
| Working Capital | 182.26 M | |||
| Current Asset | 253.11 M | |||
| Current Liabilities | 60.44 M | |||
| Net Asset | 348.94 M |
About ImmunoGen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmunoGen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoGen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoGen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ImmunoGen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmunoGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmunoGen will appreciate offsetting losses from the drop in the long position's value.Moving against ImmunoGen Stock
| 0.78 | VNTN | VentureNet Capital | PairCorr |
| 0.72 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.41 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.35 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
The ability to find closely correlated positions to ImmunoGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ImmunoGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ImmunoGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ImmunoGen to buy it.
The correlation of ImmunoGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ImmunoGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ImmunoGen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ImmunoGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |